RY 169.51 -1.1719% SHOP 175.85 -3.2036% TD 85.4 -0.187% ENB 59.6 -1.715% BN 84.78 -1.4873% TRI 250.65 2.1186% CNQ 43.69 0.9007% CP 110.72 -0.5926% CNR 146.88 0.7891% BMO 142.84 -0.6054% BNS 72.34 -0.0829% CSU 4896.4902 0.1981% CM 87.07 -0.9668% MFC 45.08 6.5217% ATD 71.13 -0.6425% NGT 68.13 0.9932% TRP 64.42 -1.2872% SU 56.73 -0.0176% WCN 266.69 -0.146% L 176.74 -1.5157%
Last update at 2025-02-20T19:16:00Z
Royalty Pharma Announces R&D Funding Collaboration With Biogen
Wed 12 Feb 25, 11:30 AMRoyalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates
Tue 11 Feb 25, 12:33 PMRoyalty Pharma Reports Q4 and Full Year 2024 Results
Tue 11 Feb 25, 12:15 PMRoyalty Pharma Earnings: What To Look For From RPRX
Mon 10 Feb 25, 01:03 PMIs Now The Time To Put Royalty Pharma (NASDAQ:RPRX) On Your Watchlist?
Sun 09 Feb 25, 02:05 PMRoyalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Wed 29 Jan 25, 02:00 PMWhy Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now?
Thu 23 Jan 25, 11:29 AMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 230.06M | 1241.20M | 1702.00M | 2461.42M | 1517.86M |
Minority interest | 187.23M | 621.47M | 726.91M | 35.88M | 63.87M |
Net income | 42.83M | 478.75M | 555.00M | 2348.53M | 1377.73M |
Selling general administrative | 227.30M | 182.83M | 182.00M | 103.44M | 61.91M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 2231.55M | 2266.47M | 2033.89M | 1814.25M | 1658.93M |
Reconciled depreciation | 5.67M | 23.00M | 23.06M | 23.92M | 33.27M |
Ebit | 977.50M | 1430.71M | 1595.00M | 2623.18M | 1380.35M |
Ebitda | 983.17M | 1482.08M | 1882.00M | 2637.30M | 1413.61M |
Depreciation and amortization | 5.67M | 51.36M | 287.00M | 14.13M | 33.27M |
Non operating income net other | 110.96M | -23.37200M | 263.61M | - | - |
Operating income | 977.50M | 1430.71M | 1595.00M | 2623.18M | 1364.45M |
Other operating expenses | 1314.32M | 858.75M | 527.00M | -808.92200M | 430.45M |
Interest expense | 187.96M | 166.14M | 157.00M | 268.57M | 279.96M |
Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
Interest income | 78.33M | 53.53M | 28.38M | 22.33M | 24.44M |
Net interest income | -109.62600M | -112.60700M | -157.00000M | -246.24400M | -255.51500M |
Extraordinary items | - | - | - | - | - |
Non recurring | 1520.07M | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 187.23M | 762.45M | 1147.00M | 349.33M | 433.37M |
Total revenue | 2237.22M | 2289.46M | 2122.00M | 1814.25M | 1794.89M |
Total operating expenses | 1314.32M | 858.75M | 527.00M | -808.92200M | 430.45M |
Cost of revenue | 5.67M | 23.00M | 88.11M | - | 135.96M |
Total other income expense net | -747.43500M | -189.51400M | 107.00M | -161.75700M | 408.92M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 230.06M | 1241.20M | 1689.08M | 2461.42M | 1517.86M |
Net income applicable to common shares | 42.83M | 619.73M | 975.04M | 2348.53M | 1377.73M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 16381.85M | 16813.47M | 17515.87M | 21097.04M | 12449.90M |
Intangible assets | 1.78M | - | 5.67M | 28.67M | 51.72M |
Earning assets | - | - | - | - | - |
Other current assets | 3.80M | 90.52M | 6.63M | 8.60M | 0.09M |
Total liab | 6297.56M | 7288.09M | 7267.32M | 6124.00M | 6308.46M |
Total stockholder equity | 6526.50M | 5628.15M | 5776.59M | 9896.00M | 6105.56M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 146.21M | 161.37M | 165.63M | 297.11M | 9.21M |
Common stock | 0.04M | 0.11M | 0.11M | 0.10M | 3282.52M |
Capital stock | 0.11M | 0.11M | 0.11M | 0.10M | 3282.52M |
Retained earnings | 2517.58M | 1964.69M | 2255.18M | 1920.63M | 2825.21M |
Other liab | - | 2.50M | - | - | - |
Good will | - | - | - | - | - |
Other assets | - | 13508.24M | 13722.39M | 5076.75M | 10930.00M |
Cash | 477.01M | 1710.75M | 1541.05M | 1009.00M | 283.68M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 161.38M | 1166.78M | 171.25M | 307.89M | 333.42M |
Current deferred revenue | - | - | - | - | 31.04M |
Net debt | 5658.27M | 5405.57M | 5555.02M | 4807.58M | 5954.44M |
Short term debt | - | 997.51M | -6891.67000M | 281.98M | 281.98M |
Short long term debt | - | 997.51M | - | - | 281.98M |
Short long term debt total | 6135.28M | 7116.32M | 7096.07M | 5816.58M | 6238.12M |
Other stockholder equity | 4008.81M | 3663.35M | 3504.82M | 7940.87M | -4.26600M |
Property plant equipment | - | - | - | - | - |
Total current assets | 1274.19M | 2554.91M | 2878.21M | 2696.90M | 832.07M |
Long term investments | 15101.14M | 14116.58M | 14358.04M | 12972.88M | 11478.15M |
Net tangible assets | - | 5628.15M | 5770.92M | 4790.11M | 6053.83M |
Short term investments | 18.30M | 717.04M | 1262.22M | 983.00M | 509.53M |
Net receivables | 775.09M | 36.60M | 68.31M | 39.17M | 38.77M |
Long term debt | 6135.28M | 6118.81M | 7096.07M | 5816.58M | 5956.14M |
Inventory | - | - | - | 657.14M | - |
Accounts payable | 15.16M | 7.91M | 5.62M | 10.78M | 11.18M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | 3897.22M | 4471.95M | 5077.04M | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | 0.06M | - | 16.49M | 34.40M | 2.09M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | 0.11M | 0.11M | 0.10M | 3282.52M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | 1964.69M | 2255.18M | 1920.63M | - |
Treasury stock | - | -2.80600M | -2.71500M | -2.31700M | -4.26600M |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 14093.40M | 29.63M | 4.14M | 28.60M | 87.95M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 15107.66M | 14258.56M | 14637.65M | 13323.39M | 11617.82M |
Capital lease obligations | - | - | - | - | - |
Long term debt total | - | 6118.81M | 7096.07M | 5816.58M | 5956.14M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -1152.79400M | -1832.50300M | -3094.16000M | -2116.14200M | 573.02M |
Change to liabilities | 2.29M | -4.58600M | -0.76600M | 6.50M | 1.35M |
Total cashflows from investing activities | -1029.42100M | -1870.28000M | -2759.32000M | -2153.62500M | 303.42M |
Net borrowings | -1.34700M | 1259.49M | 728.12M | -294.00000M | -294.00000M |
Total cash from financing activities | -944.85600M | 385.11M | 1487.00M | -1191.62600M | -1379.10100M |
Change to operating activities | -6.08000M | 8.39M | 76.36M | -33.63800M | -11.54100M |
Net income | 230.06M | 1241.20M | 1701.95M | 2461.42M | 1517.86M |
Change in cash | 169.70M | 532.37M | 763.00M | -1640.52900M | 542.64M |
Begin period cash flow | 1541.05M | 1008.68M | 246.00M | 1924.21M | 1381.57M |
End period cash flow | 1710.75M | 1541.05M | 1009.00M | 283.68M | 1924.21M |
Total cash from operating activities | 2143.98M | 2017.54M | 2034.63M | 1667.24M | 1618.32M |
Issuance of capital stock | 0.00000M | 0.00000M | 1908.74M | - | 0.00000M |
Depreciation | 5.67M | 23.00M | 23.06M | 23.92M | 33.27M |
Other cashflows from investing activities | 123.37M | -37.77700M | 334.84M | -258.84000M | -258.84000M |
Dividends paid | -333.32200M | -285.18400M | -397.00000M | -739.27600M | 814.36M |
Change to inventory | - | - | - | - | - |
Change to account receivables | 2543.69M | 2295.72M | 162.32M | 287.73M | 500.40M |
Sale purchase of stock | -144.11500M | -479.60400M | 11891.00M | - | 0.00000M |
Other cashflows from financing activities | -611.53400M | 670.30M | -706.00000M | -158.35000M | -270.74200M |
Change to netincome | 64.12M | 37.52M | 50.04M | -978.59400M | -296.01900M |
Capital expenditures | 2041.15M | 0.52M | 2197.00M | 1721.29M | 269.59M |
Change receivables | - | - | - | - | - |
Cash flows other operating | 2079.86M | 1980.02M | 1984.59M | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | 169.70M | 532.37M | 762.48M | - | - |
Change in working capital | 32.66M | -16.32200M | -1884.00900M | -1673.50800M | -1562.37900M |
Stock based compensation | 2.17M | 2.44M | 5.43M | - | - |
Other non cash items | 1873.41M | 2289.58M | 2122.71M | 855.40M | 1629.57M |
Free cash flow | 4185.13M | 2018.06M | 4231.63M | 1667.24M | 1887.91M |
Sector: Healthcare Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
RPRX Royalty Pharma Plc |
0.51 1.56% | 33.10 | 14.97 | 8.31 | 7.16 | 1.93 | 7.44 | 9.28 |
NVO Novo Nordisk A/S |
0.31 0.37% | 83.71 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
NONOF Novo Nordisk A/S |
1.01 1.22% | 83.81 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
VRTX Vertex Pharmaceuticals Inc |
7.45 1.58% | 479.21 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
REGN Regeneron Pharmaceuticals Inc |
11.20 1.63% | 696.86 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
110 East 59th Street, New York, NY, United States, 10022
Name | Title | Year Born |
---|---|---|
Mr. Pablo Gerardo Legorreta | Founder, Chairman & CEO | 1964 |
Mr. Terrance P. Coyne | Exec. VP & CFO | NA |
Mr. George Wingate Lloyd | Exec. VP of Investments & Chief Legal Officer | 1959 |
Mr. Christopher Hite | Vice Chairman & Exec. VP | 1967 |
Dr. Marshall Urist M.D., Ph.D. | Exec. VP and Head of Research & Investments | NA |
Mr. Arthur R. McGivern J.D. | Exec. VP of Investments & Gen. Counsel | NA |
Ms. Kristin Stafford | Sr. VP & Chief Accounting Officer | NA |
Dr. James Folmar Reddoch Ph.D. | Exec. VP of Investments & Chief Scientific Officer | 1970 |
Mr. George Grofik C.F.A., CPA | Sr. VP and Head of Investor Relations & Communications | NA |
Ms. Alessandra Sassun | VP & Head of Human Capital | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.